Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00405327 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00405327 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 16 participants.
The verdict
NCT00405327, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor, can generally be effectively treated with a combination of surgery, radiation and chemotherapy. However, patients with metastatic or relapsed disease have a very poor prognosis. New approaches to the management of these difficult groups of patients are needed. There is evidence to suggest that solid tumors may be good candidates for immunotherapy approaches. In fact, recent experimental evidence indicates that the period of lymphopenia that occurs after stem cell transplant may be an opportune time to use an immunotherapy treatment approach. In light of the very poor prognosis of young patients with advanced solid tumors, this treatment approach warrants further investigation.
Interventions
- BIOLOGICAL Tumor lysate-pulsed dendritic cell (DC) vaccine
- OTHER Hematopoietic stem cell transplantation (HSCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2006-06 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00405327
The ClinicalTrials.gov registry entry for NCT00405327 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tumor lysate-pulsed dendritic cell (DC) vaccine is the first listed.
NCT00405327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00405327 about?
NCT00405327 is a clinical study titled "A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation". Localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor, can generally be effectively treated with a combination of surgery, radiation and chemotherapy. However, patients with metastatic or relapsed disease have a very poor prognosis. New approaches to the management of these diffi...
What is the current status of trial NCT00405327?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2006-06. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00405327?
The interventions under investigation include: Tumor lysate-pulsed dendritic cell (DC) vaccine (BIOLOGICAL), Hematopoietic stem cell transplantation (HSCT) (OTHER).
Who is sponsoring clinical trial NCT00405327?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.